Rezafungin
Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.
分子量
1226.4000 g/mol
LogP
2.90
TPSA
366.00 Ų
Lipinski 五规则
不符合
Pharmacokinetics (PK)
Pharmacodynamics (PD)
二维结构
Cite this structure
Embed this structure
SMILES
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1
InChI
InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1
Molecular Formula
C63H85N8O17+
HBD / HBA
13 / 17
可旋转键数
18
重原子数
88
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.
Yes, Rezafungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989945. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 78318119. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rezafungin"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rezafungin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rezafungin/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rezafungin/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rezafungin"></drugfyi-drug>